Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
British Journal of Cancer
|
February 19, 2004
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
M Lotem, E Shiloni, I Pappo, et al.
British Journal of Cancer
|
June 27, 2002
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer
M Lotem, T Peretz, O Drize, et al.
Tissue Antigens
|
June 8, 2011
HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine
M Lotem, L Kadouri, S Merims, et al.
European Journal of Human Genetics : EJHG
|
August 22, 2000
Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families
E Yakobson, P Shemesh, E Azizi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 14, 2006
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients
S Peters, V Voelter, L Zografos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2022
Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS)
A Zer, O Icht, L Yosef, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
G V Long, M S Carlino, C McNeil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G V Long, A Arance, L Mortier, et al.
Journal of Skin Cancer
|
February 1, 2013
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma
M Klein, M Lotem, T Peretz, et al.
Nature Communications
|
September 21, 2017
Predictors of responses to immune checkpoint blockade in advanced melanoma
N Jacquelot, M P Roberti, D P Enot, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
British Journal of Cancer
|
February 19, 2004
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
M Lotem, E Shiloni, I Pappo, et al.
British Journal of Cancer
|
June 27, 2002
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer
M Lotem, T Peretz, O Drize, et al.
Tissue Antigens
|
June 8, 2011
HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine
M Lotem, L Kadouri, S Merims, et al.
European Journal of Human Genetics : EJHG
|
August 22, 2000
Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families
E Yakobson, P Shemesh, E Azizi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 14, 2006
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients
S Peters, V Voelter, L Zografos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2022
Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS)
A Zer, O Icht, L Yosef, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
G V Long, M S Carlino, C McNeil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G V Long, A Arance, L Mortier, et al.
Journal of Skin Cancer
|
February 1, 2013
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma
M Klein, M Lotem, T Peretz, et al.
Nature Communications
|
September 21, 2017
Predictors of responses to immune checkpoint blockade in advanced melanoma
N Jacquelot, M P Roberti, D P Enot, et al.
Page
of 7